Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2018; 9:15165.

The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas

Philip Carter _, Costi Alifrangis, Pramodh Chandrasinghe, Biancastella Cereser, Lisa Del Bel Belluz, Cosimo Alex Leo, Nina Moderau, Neha Tabassum, Janindra Warusavitarne, Jonathan Krell and Justin Stebbing

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:11371-11376. https://doi.org/10.18632/oncotarget.24257

Metrics: PDF 959 views  |   HTML 1637 views  |   ?  


Abstract

Philip Carter1, Costi Alifrangis2, Pramodh Chandrasinghe1,3,4, Biancastella Cereser1, Lisa Del Bel Belluz1, Cosimo Alex Leo4, Nina Moderau1, Neha Tabassum1, Janindra Warusavitarne4, Jonathan Krell1 and Justin Stebbing1

1Department of Surgery and Cancer, Imperial College, London, UK

2Department of Medical Oncology, Imperial College, London, UK

3Department of Surgery, University of Kelaniya, Kelaniya, Sri Lanka

4Department of Colorectal Surgery, St Mark’s Hospital, London, UK

Correspondence to:

Philip Carter, email: phil.carter@imperial.ac.uk

Keywords: tumor profiling; colorectal adenocarcinoma; cancer treatment

Received: July 29, 2017     Accepted: November 15, 2017     Published: January 16, 2018

ABSTRACT

We evaluated the benefit of tailoring treatments for a colorectal adenocarcinoma cancer cohort according to tumor molecular profiles, by analyzing data collected on patient responses to treatments that were guided by a tumor profiling technology from Caris Life Sciences. DNA sequencing and immunohistochemistry were the main tests that predictions were based upon, but also fragment analysis, and in situ hybridization. The status of the IHC biomarker for the thymidylate synthase receptor was a good indicator for future survival. Data collected for the clinical treatments of 95 colorectal adenocarcinoma patients was retrospectively divided into two groups: the first group was given drugs that always matched recommended treatments as suggested by the tumor molecular profiling service; the second group received at least one drug after profiling that was predicted to lack benefit. In the matched treatment group, 19% of patients were deceased at the end of monitoring compared to 49% in the unmatched group, indicating a benefit in mortality by tumor molecular profiling colorectal adenocarcinoma patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24257